Edition:
United Kingdom

FibroGen Inc (FGEN.OQ)

FGEN.OQ on NASDAQ Stock Exchange Global Select Market

42.40USD
15 Dec 2017
Change (% chg)

$0.45 (+1.07%)
Prev Close
$41.95
Open
$41.80
Day's High
$43.50
Day's Low
$40.75
Volume
1,580,021
Avg. Vol
233,626
52-wk High
$60.15
52-wk Low
$19.30

Select another date:

Wed, Nov 8 2017

BRIEF-Fibrogen Inc reports Q3 loss per share $0.50

* Q3 earnings per share view $-0.37 -- Thomson Reuters I/B/E/S

BRIEF-Fibrogen announces acceptance by china FDA of roxadustat NDA for treatment of anemia associated with dialysis and non-dialysis kidney disease

* Fibrogen announces acceptance by china FDA of roxadustat new drug application (NDA) for treatment of anemia associated with dialysis and non-dialysis chronic kidney disease (CKD)

BRIEF-Fibrogen's ‍Pamrevlumab was well tolerated with no safety risks

* ‍Announced results from co's phase 2b randomized, double-blind, placebo-controlled study in patients with idiopathic pulmonary fibrosis​

BRIEF-Fibrogen announces pricing of follow-on offering of common stock

* Fibrogen, Inc. announces pricing of follow-on offering of common stock

BRIEF-FibroGen announces proposed follow-on offering of common stock

* Fibrogen Inc announces proposed follow-on offering of common stock

BRIEF-Fibrogen ‍net loss per diluted share for quarter ended June 30 was $0.48

* Fibrogen Inc - ‍net loss per basic and diluted share for quarter ended June 30, 2017 was $0.48 - SEC filing​

BRIEF-Fibrogen Inc reports Q2 loss per share $0.48

* Q2 earnings per share view $-0.47 -- Thomson Reuters I/B/E/S

Select another date: